Denali Therapeutics
NASDAQ · DNLI·South San Francisco, CA·Small-cap·Approved
Clinical and now commercial-stage biotech focused on neurodegenerative and lysosomal storage diseases, built on the proprietary Transport Vehicle (TV) platform for brain-penetrant biologics. Lead asset tividenofusp alfa (DNL310) launched for Hunter syndrome (MPS II) following FDA accelerated approval; Phase 2 LUMA Parkinson's readout for BIIB122/DNL151 expected mid-2026.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| DNLI Corporate Presentation — January 2026 | JPM Healthcare | January 13, 2026 | 37 |